## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1033.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. The Truth About Eli Lilly and Company: Why Everyone on Wall Street Is Obsessed Right Now**
- Source: AD HOC NEWS | 20251231T120755 | Somewhat-Bullish | Relevance: 100%
- Eli Lilly (LLY) has become a Wall Street obsession, fueled by the success of its weight-loss and diabetes drugs. While the hype around the company's products is significant, driving a "mega-pharma" valuation, investors need to consider if current prices justify future growth expectations, especially given the inherent volatility and competition in the market. The article delves into product story, future runway, and risk factors to help investors decide if LLY is a worthwhile investment or if the hype is already fully priced in.

**2. Simplify Asset Management Inc. Sells 4,453 Shares of Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251231T110831 | Bullish | Relevance: 100%
- Simplify Asset Management Inc. significantly reduced its holdings in Eli Lilly and Company (LLY) by 31.5% in the third quarter, selling 4,453 shares but still retaining 9,664 shares valued at $7,374,000, making it their 20th largest position. Eli Lilly recently exceeded Q3 expectations with higher EPS and revenue, and provided positive FY2025 guidance. The company also increased its quarterly dividend to $1.73 per share, payable on March 10th.

**3. New Eli Lilly and Company Commercial Divides Viewers Over Alleged Pro-Obesity Message**
- Source: Inquisitr News | 20260102T140812 | Neutral | Relevance: 100%
- Eli Lilly and Company's new commercial, "My Business," has sparked controversy, with some viewers interpreting it as promoting obesity while others see it as encouraging positive body image and destigmatizing obesity. The ad, which features a man asserting his health is "nobody's business," aired shortly after Lilly unveiled a new obesity drug. Reactions online are strongly divided, with critics calling the ad "bizarre" and "idiocy" for a pharmaceutical company, while supporters praise its message as "powerful" and validating for those dealing with obesity.

**4. Miracle Mile Advisors LLC Grows Stock Position in Eli Lilly and Company $LLY**
- Source: MarketBeat | 20260102T110749 | Bullish | Relevance: 96%
- Miracle Mile Advisors LLC increased its stake in Eli Lilly and Company by 7.9% in Q3, now holding 19,766 shares valued at $15.08 million. Eli Lilly also reported strong Q3 earnings, beating expectations, and announced a raised quarterly dividend. The company maintains an average analyst rating of "Moderate Buy" with a target price of $1,155.36.

**5. Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market**
- Source: CNBC | 20260101T060953 | Neutral | Relevance: 84%
- Novo Nordisk is facing a pivotal year in 2026, marked by challenges such as pricing pressures and patent expiries, especially in the crucial U.S. market. Despite its stock experiencing its worst year on record, the recent FDA approval of its oral weight-loss pill, Wegovy, offers a potential opportunity to regain investor confidence and compete with Eli Lilly. The company's ability to navigate competition from rival drugs and cheaper copycats, alongside its new leadership's performance in improving U.S. operations, will be critical for its future growth.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-12-03 | Guggenheim | $1163 | $1036 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.90M) |
| Sells | 26 ($18470.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $18471M sold (26 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 33.1x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($18471.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $968.5B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 33.1 |
| Current P/E | 45.7 |
| YoY Growth | 37.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.1% to 1.2% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.31), momentum weakening. OFD pattern: +DLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.21% (CS: 62) | Neutral |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | -1.31 | Bearish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.305x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1080.36
- **Stop Loss:** $1033.00 (4.4% risk)
- **Target:** $1127.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 30
- **Position Value:** $32,410.80
- **Portfolio %:** 32.41%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*